An investigational monoclonal antibody, isatuximab, has been designed to target a specific epitope on the CD38 receptor of a plasma cell. The drug has been designed to activate
The post FDA accepts to review Sanofi’s multiple myeloma candidate isatuximab appeared first on Pharmaceutical Business review.
Original Article: FDA accepts to review Sanofi’s multiple myeloma candidate isatuximab